Pharma Focus Asia Magazine

Foreword

CLINICAL TRIALS

Leveraging wearables effectively

An estimated million people use connected wearable devices according to IMARC

Manufacturing

FLEXIBLE FACILITIES

Manufacturing trends offering benefits

In the early st century one of if not the primary goal of a pharmaceutical facility was to maintain large production lines and attain exceptional productivity and product throughput

A QUALITY BY DESIGN APPROACH

Development of a robust control strategy for manufacturing

By the Global Topical Drug Delivery market is expected to exceed more than US Billion

MESSY MARKETING

Deliberate disordering can improve your strategic marketing planning

In any large life science company strategic marketing planning is a carefully organised timetabled and structured process

Clinical Trials

HEALTHCARE EVOLUTION

THE GROWING USE OF WEARABLES IN CLINICAL TRIALS

Pharmaceutical development is in crisis According to the Tufts Center for the Study of Drug Development it now costs US billion to bring a drug to market which is a per cent increase in years

Compelling Pre-clinical Models

For better prognosis in clinical trials

Preclinical trials are the windows of clinical phases in drug discovery and developmental practice

Research & Development

COMPUTER AIDED DRUG DESIGN IN PHARMA R&D

The number of new US FDA approved drugs is declining in spite of lots advances made in science

FOUND IN TRANSLATION

Building an early development strategy for complex biologics

Biologics are drugs isolated from natural sources and include proteins nucleic acids viruses and cells

Strategy

NOVO NORDISK PHARMATECH A/S

ENSURING QUALITY ASSURANCE

In this highly competitive market quality has become the market differentiator for almost all products and services

Is Blockchain the Right Technology for the Pharma Supply Chain?

A marriage between blockchain and the pharma supply chain is not preordained

REGULATORY ASPECTS OF GENOTOXIC IMPURITIES

As per ICH QA guidelines impurity in a drug substance is any component of the drug substance that is not the chemical entity defined as the drug substance and as per ICH QB guidelines impurity in any component of the drug product that is not the chemical entity defined as the drug substance or an excipient in the drug product

DRUG PRICING FOR PERSONALISED MEDICINE

IS INDICATION-BASED PRICE THE SOLUTION?

Personalised medicine is going to change the shape of the pharmaceutical market in the years to come

Advertorials

DATWYLER’S STARTER PACK

Successfully mastering the global healthcare challenges

As the healthcare industry faces increased complexity and stricter requirements for drug development market leaders are looking for new and innovative ways to address these concerns

AirBridgeCargo - Air frieght solutions for your Pharma Matcon Efficently handling tablets and powders in IBC's Swiss World Cargo - Pharmaceuticals & Healthcare MECO - 90 Years